201 related articles for article (PubMed ID: 34458816)
21. Pharmacogenomics of tamoxifen and aromatase inhibitors.
Ingle JN
Cancer; 2008 Feb; 112(3 Suppl):695-699. PubMed ID: 18072234
[TBL] [Abstract][Full Text] [Related]
22. Biophysical characterization of Aptenodytes forsteri cytochrome P450 aromatase.
Zarate-Perez F; Velázquez-Fernández JB; Jennings GK; Shock LS; Lyons CE; Hackett JC
J Inorg Biochem; 2018 Jul; 184():79-87. PubMed ID: 29684698
[TBL] [Abstract][Full Text] [Related]
23. Use of aromatase inhibitors in breast carcinoma.
Santen RJ; Harvey HA
Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
[TBL] [Abstract][Full Text] [Related]
24. Interference of endocrine disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish.
Cheshenko K; Pakdel F; Segner H; Kah O; Eggen RI
Gen Comp Endocrinol; 2008 Jan; 155(1):31-62. PubMed ID: 17459383
[TBL] [Abstract][Full Text] [Related]
25. Aromatase inhibitors in the treatment of breast cancer.
Brueggemeier RW; Hackett JC; Diaz-Cruz ES
Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
[TBL] [Abstract][Full Text] [Related]
26. Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
Spinello A; Martini S; Berti F; Pennati M; Pavlin M; Sgrignani J; Grazioso G; Colombo G; Zaffaroni N; Magistrato A
Eur J Med Chem; 2019 Apr; 168():253-262. PubMed ID: 30822713
[TBL] [Abstract][Full Text] [Related]
27. Aromatase, aromatase inhibitors, and breast cancer.
Brueggemeier RW
Am J Ther; 2001; 8(5):333-44. PubMed ID: 11550075
[TBL] [Abstract][Full Text] [Related]
28. Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women.
Agarwal VR; Ashanullah CI; Simpson ER; Bulun SE
J Clin Endocrinol Metab; 1997 Jan; 82(1):70-4. PubMed ID: 8989235
[TBL] [Abstract][Full Text] [Related]
29. Aromatase, its inhibitors and their use in breast cancer treatment.
Brodie AM
Pharmacol Ther; 1993 Dec; 60(3):501-15. PubMed ID: 8073072
[TBL] [Abstract][Full Text] [Related]
30. Structure-function studies of aromatase and its inhibitors: a progress report.
Chen S; Zhang F; Sherman MA; Kijima I; Cho M; Yuan YC; Toma Y; Osawa Y; Zhou D; Eng ET
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):231-7. PubMed ID: 14623516
[TBL] [Abstract][Full Text] [Related]
31. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
32. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.
Bulun SE; Economos K; Miller D; Simpson ER
J Clin Endocrinol Metab; 1994 Dec; 79(6):1831-4. PubMed ID: 7989490
[TBL] [Abstract][Full Text] [Related]
33. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
34. Nonsteroidal aromatase inhibitors: recent advances.
Recanatini M; Cavalli A; Valenti P
Med Res Rev; 2002 May; 22(3):282-304. PubMed ID: 11933021
[TBL] [Abstract][Full Text] [Related]
35. Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7.
Li F; Ye L; Lin SM; Leung LK
Mol Cell Endocrinol; 2011 Sep; 344(1-2):51-8. PubMed ID: 21741436
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE; Strasser K
Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors for breast cancer in postmenopausal women.
Campos SM
Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
[TBL] [Abstract][Full Text] [Related]
38. Aromatase and breast cancer.
Chen S
Front Biosci; 1998 Aug; 3():d922-33. PubMed ID: 9696881
[TBL] [Abstract][Full Text] [Related]
39. Identification of a transcriptional regulatory factor for human aromatase cytochrome P450 gene expression as nuclear factor interleukin-6 (NF-IL6), a member of the CCAAT/enhancer-binding protein family.
Toda K; Akira S; Kishimoto T; Sasaki H; Hashimoto K; Yamamoto Y; Sagara Y; Shizuta Y
Eur J Biochem; 1995 Jul; 231(2):292-9. PubMed ID: 7635140
[TBL] [Abstract][Full Text] [Related]
40. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study.
Kao YC; Cam LL; Laughton CA; Zhou D; Chen S
Cancer Res; 1996 Aug; 56(15):3451-60. PubMed ID: 8758911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
